Tissue engineered construct for supplementing or replacing a damaged organ

• US 20070059293A1
• Filed: 08/21/2006
• Published: 03/15/2007
• Est. Priority Date: 02/05/2002
• Status: Abandoned Application

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Atala, Anthony
• Application Number:
  US11/507,402
• Publication Number:
  US 20070059293A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3839 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: C12N 2799/022 where the vector is derived from an adenovirus
• CPC Class Codes: C12N 5/0062 General methods for three-dimensional culture

Abstract

The present invention provides methods and compositions for supplementing or replacing a damaged organ. The damaged organ to be supplemented or replaced in accordance with the present invention include, for example, kidney, heart, liver, spleen, pancreas, bladder, ureter and urethra. In one embodiment, the tissue-engineered construct of the invention has has at least the following characteristics: (a) differentiated cells on a three-dimensional biocompatible scaffold, wherein the differentiated cells originated from transferred pluripotent cells; and (b) at least one physiological function of the organ.

Claims

1. A tissue-engineered construct for supplementing or replacing a damaged organ, the construct having the following characteristics:

(a) differentiated cells on a three-dimensional biocompatible scaffold, wherein the differentiated cells originated from transferred pluripotent cells; and

(b) at least one physiological function of the organ.

2. The tissue-engineered construct of claim 1, wherein the damaged organ is select from the group consisting of kidney, heart, liver, spleen, pancreas, bladder, ureter and urethra.

3. The tissue-engineered construct of claim 1, wherein the scaffold comprises a polymer, hydrogel or decellularized tissue.

4. The tissue-engineered construct of claim 1, wherein the pluripotent cells are differentiated to result in a desired cell type prior to contact with the scaffold.

5. The tissue-engineered construct of claim 1, wherein the pluripotent cells are human stem cells.

6. The tissue-engineered construct of claim 5, wherein the human stem cells are selected from the group consisting of pluripotent hematopoietic stem cells, embryonic stem cells and adult somatic stem cells.

7. The tissue-engineered construct of claim 1, wherein the pluripotent cells are obtained from tissues selected from the group consisting of bone marrow, muscle, adipose tissue, liver, heart, lung and nervous system.

8. The tissue-engineered construct of claim 7, wherein the tissues are selected from the group consisting of adult, embryonic or fetal tissues.

9. The tissue-engineered construct of claim 1, wherein the construct is selected to supplement the activity of a kidney and the physiological function of the organ is excretion of metabolic waste.

10. The tissue-engineered construct of claim 9, wherein the scaffold comprises a porous membrane structure having an external surface defining an enclosed internal space having at least one effluent channel extending from the construct.

11. A method of producing a tissue-engineered construct for supplementing or replacing a damaged organ comprising:

(a) contacting pluripotent cells with a three-dimensional biocompatible scaffold such that the cells attach to the scaffold;

(b) placing the pluripotent cells under conditions to result in differentiation to a desired cell type; and

(c) culturing the cells attached to the scaffold to produce a tissue layer having at least one physiological function of the organ, thereby producing a tissue-engineered construct.

12. The method of claim 11, wherein the differentiated cells originated from transferred pluripotent cells and said pluripotent cells were placed under conditions that caused differentiation.

13. The method of claim 11, wherein the damaged organ is select from the group consisting of kidney, heart, liver, spleen, pancreas, bladder, ureter and urethra.

14. The method of claim 11, wherein the scaffold comprises a polymer, hydrogel or decellularized tissue.

15. The method of claim 11, wherein the pluripotent cells are differentiated to result in a desired cell type prior to contact with the scaffold.

16. The method of claim 11, wherein the pluripotent cells are human stem cells.

17. The method of claim 16, wherein the human stem cells are selected from the group consisting of pluripotent hematopoietic stem cells, embryonic stem cells and adult somatic stem cells.

18. The method of claim 11, wherein the pluripotent cells are obtained from tissues selected from the group consisting of bone marrow, muscle, adipose tissue, liver, heart, lung and nervous system.

19. The method claim 18, wherein the tissues are selected from the group consisting of adult, embryonic or fetal tissues.

20. The method of claim 11, wherein the construct is selected to supplement the activity of a kidney and the physiological function of the organ is excretion of metabolic waste.

21. The method of claim 11, wherein the scaffold comprises a porous membrane structure having an external surface defining an enclosed internal space having at least one effluent channel extending from the construct.